HomeCompareTLGT vs JNJ

TLGT vs JNJ: Dividend Comparison 2026

TLGT yields 27377.52% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TLGT wins by $1.188659204665963e+21M in total portfolio value
10 years
TLGT
TLGT
● Live price
27377.52%
Share price
$0.17
Annual div
$47.50
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.188659204665963e+21M
Annual income
$1,180,179,287,020,189,700,000,000,000.00
Full TLGT calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — TLGT vs JNJ

📍 TLGT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTLGTJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TLGT + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TLGT pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TLGT
Annual income on $10K today (after 15% tax)
$2,327,089.34/yr
After 10yr DRIP, annual income (after tax)
$1,003,152,393,967,161,200,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, TLGT beats the other by $1,003,152,393,967,161,200,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TLGT + JNJ for your $10,000?

TLGT: 50%JNJ: 50%
100% JNJ50/50100% TLGT
Portfolio after 10yr
$594329602332981460992.00M
Annual income
$590,089,643,510,094,850,000,000,000.00/yr
Blended yield
99.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TLGT
Analyst Ratings
1
Buy
3
Hold
Consensus: Hold
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TLGT buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTLGTJNJ
Forward yield27377.52%2.13%
Annual dividend / share$47.50$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$1.188659204665963e+21M$30.3K
Annual income after 10y$1,180,179,287,020,189,700,000,000,000.00$4,689.40
Total dividends collected$1.188100965028857e+21M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: TLGT vs JNJ ($10,000, DRIP)

YearTLGT PortfolioTLGT Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$2,748,452$2,737,752.16$10,592$272.30+$2.74MTLGT
2$706,172,699$703,231,854.70$11,289$357.73+$706.16MTLGT
3$169,619,770,362$168,864,165,574.45$12,123$472.89+$169619.76MTLGT
4$38,088,480,331,187$37,906,987,176,899.56$13,141$629.86+$38088480.32MTLGT
5$7,995,983,294,959,344$7,955,228,621,004,974.00$14,408$846.81+$7995983294.94MTLGT
6$1,569,355,212,688,684,500$1,560,799,510,563,078,100.00$16,021$1,151.60+$1569355212688.67MTLGT
7$287,973,521,392,263,700,000$286,294,311,314,686,770,000.00$18,122$1,588.22+$287973521392263.69MTLGT
8$49,405,729,451,981,220,000,000$49,097,597,784,091,490,000,000.00$20,930$2,228.20+$49405729451981216.00MTLGT
9$7,925,156,678,292,761,000,000,000$7,872,292,547,779,143,000,000,000.00$24,792$3,191.91+$7925156678292761600.00MTLGT
10$1,188,659,204,665,962,900,000,000,000$1,180,179,287,020,189,700,000,000,000.00$30,274$4,689.40+$1.188659204665963e+21MTLGT

TLGT vs JNJ: Complete Analysis 2026

TLGTStock

Teligent, Inc., formerly Igi Laboratories Inc, is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 35 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2018. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 20 Abbreviated New Drug Application (ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2018.

Full TLGT Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this TLGT vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TLGT vs SCHDTLGT vs JEPITLGT vs OTLGT vs KOTLGT vs MAINTLGT vs ABBVTLGT vs MRKTLGT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.